SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Citigroup Inc., et al. – ‘424B2’ on 5/11/21

On:  Tuesday, 5/11/21, at 4:15pm ET   ·   Accession #:  1193125-21-157591   ·   File #s:  333-255302, -01, -02, -03

Previous ‘424B2’:  ‘424B2’ on 5/11/21   ·   Next:  ‘424B2’ on 5/11/21   ·   Latest:  ‘424B2’ on 5/14/24   ·   15 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/11/21  Citigroup Inc.                    424B2                  1:77K                                    Donnelley … Solutions/FA
          Citigroup Capital XVIII
          Citigroup Capital XIII
          Citigroup Global Markets Holdings Inc.

Prospectus – Primary Offering or Shelf Securities   —   Rule 424(b)(2)

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 424B2       Prospectus - Primary Offering or Shelf Securities   HTML     26K 


Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Description of the Securities
"Market-Making Activities
"Conflicts of Interest
"Use of Proceeds
"Where You Can Find More Information
"Forward-Looking Statements

This is an HTML Document rendered as filed.  [ Alternative Formats ]



  424B2  

Filed Pursuant to Rule 424(b)(2)
Registration Statement Nos. 333-255302,
333-255302-01,
333-255302-02
and 333-255302-03

PROSPECTUS

 

LOGO

This prospectus applies to market-making offers and sales of all outstanding debt securities, index warrants, preferred stock, depositary shares, capital securities and guarantees issued by Citigroup Inc. (“Citigroup”), its wholly-owned subsidiary trusts or corporate predecessors and all outstanding debt securities issued by Citigroup Global Markets Holdings Inc. under the following Registration Statement numbers: 33-63663, 333-12439, 333-46628, 333-48474, 333-56088, 333-68949, 333-57364, 333-68989, 333-75554, 333-102206, 333-103940, 333-105316, 333-106510, 333-108047, 333-117615, 333-122925, 333-132177, 333-132370, 333-135163, 333-142849, 333-146471, 333-157386, 333-157459, 333-172554, 333-172562, 333-186425, 333-191056, 333-192302, 333-214120, 333-216372 and 333-224495.

 

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities referenced above or determined if this prospectus or any pricing supplement, any product supplement, any prospectus supplement and accompanying prospectus describing the terms of a specific series of securities is truthful or complete. Any representation to the contrary is a criminal offense.

These securities referenced above are not deposits or savings accounts but are unsecured obligations of the applicable issuer. The securities are not insured by the Federal Deposit Insurance Corporation or any other governmental agency or instrumentality.

One or more broker-dealer subsidiaries of Citigroup, including Citigroup Global Markets Inc., expect to offer and sell the outstanding securities referenced above as part of their business, and may act as principal or agent in such transactions. These broker-dealer subsidiaries may use this prospectus in connection with these activities.

 

May 11, 2021


TABLE OF CONTENTS

 

     Page  

DESCRIPTION OF THE SECURITIES

     1  

MARKET-MAKING ACTIVITIES

     1  

Conflicts of Interest

     1  

USE OF PROCEEDS

     1  

WHERE YOU CAN FIND MORE INFORMATION

     1  

FORWARD-LOOKING STATEMENTS

     3  

 

i


DESCRIPTION OF THE SECURITIES

The securities referenced on the cover page of this prospectus have been issued and/or guaranteed under one of the Registration Statements listed on the cover of this prospectus. A pricing supplement, if any, product supplement, if any, prospectus supplement, if any, and prospectus describing each such security (each, a “disclosure document”) have been filed with the Securities and Exchange Commission and each of these disclosure documents is incorporated by reference herein in its entirety, except for any portion of each disclosure document that incorporates by reference the relevant issuer’s prior and future filings made with the SEC under Section  13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934.

MARKET-MAKING ACTIVITIES

This prospectus, together with the relevant pricing supplement, if any, product supplement, if any, prospectus supplement, if any, and prospectus describing the terms of the specific securities being offered and sold, may be used by Citigroup’s broker-dealer subsidiaries in connection with offers and sales of such securities (subject to obtaining any necessary approval of any stock exchange on which such securities are listed for any of these offers and sales) in market-making transactions at negotiated prices related to prevailing market prices at the time of sale. Any of these subsidiaries may act as principal or agent in these transactions. None of these subsidiaries is obligated to make a market in any of the securities referenced on the cover of this prospectus and any such subsidiary may discontinue any market making at any time without notice, at its sole discretion.

Conflicts of interest. Each broker-dealer subsidiary of Citigroup is a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) and may participate in distributions of the securities referenced on the cover page of this prospectus. Accordingly, the participation of any such entity in the offerings of such securities will conform with the requirements addressing conflicts of interest when distributing the securities of an affiliate set forth in FINRA Rule 5121 or will be conducted pursuant to FINRA Rule 2310, as applicable.

USE OF PROCEEDS

Neither Citigroup nor Citigroup Global Markets Holdings Inc. will receive any of the proceeds from the sale of the securities referenced on the cover page of this prospectus. All secondary market offers and sales made pursuant to this prospectus and the pricing supplement, if any, product supplement, if any, prospectus supplement, if any, and prospectus describing the terms of the specific securities being offered and sold will be for the accounts of the broker-dealer subsidiaries of Citigroup in connection with market-making transactions.

WHERE YOU CAN FIND MORE INFORMATION

As required by the Securities Act of 1933, Citigroup and Citigroup Global Markets Holdings Inc. filed a registration statement relating to the securities offered by this prospectus with the Securities and Exchange Commission (“SEC”). This prospectus is a part of that registration statement, which includes additional information.

Citigroup files annual, quarterly and current reports, proxy statements and other information with the SEC. These SEC filings are available to the public from the SEC’s web site at http://www.sec.gov. Such documents, reports and information are also available on Citigroup’s website: https://www.citigroup.com/citi/investor/sec.htm. Information on Citigroup’s website does not constitute part of this prospectus.

The SEC allows Citigroup to incorporate by reference the information it files with the SEC, which means that it can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information that Citigroup files later with the SEC will automatically update information in this prospectus. In all cases, you should rely on the later

 

1


information over different information included in this prospectus, any applicable pricing supplement, any applicable product supplement, any applicable prospectus supplement and the prospectus. Citigroup incorporates by reference the documents listed below and any future filings made with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 (File No. 1-09924):

 

   

Annual Report on Form 10-K for the year ended December 31, 2020, filed on February 26, 2021;

 

   

Quarterly Report on Form  10-Q for the quarter ended March 31, 2021, filed on May 6, 2021;

 

   

Current Reports on Form 8-K filed on January 15, 2021 (to the extent filed with the SEC), January  28, 2021, February  12, 2021, February  18, 2021, March  19, 2021, March  19, 2021, April  15, 2021 (to the extent filed with the SEC), April  29, 2021, May  4, 2021, May  4, 2021 and May 4, 2021;

 

   

Definitive Proxy Statement on Schedule 14A, filed on March 17, 2021; and

 

   

Current Report on Form 8-K, dated May 11, 2009, describing Citigroup’s common stock, including any amendments or reports filed for the purpose of updating such description.

In no event, however, will any of the information that Citigroup furnishes to, pursuant to Item 2.02 or Item 7.01 of any Current Report on Form 8-K (including exhibits related thereto) or other applicable SEC rules, rather than files with, the SEC be incorporated by reference or otherwise be included herein, unless such information is expressly incorporated herein by a reference in such furnished Current Report on Form 8-K or other furnished document.

All documents filed by Citigroup specified in Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus and before the date the broker-dealer subsidiaries of Citigroup stop offering securities pursuant to this prospectus shall be incorporated by reference in this prospectus from the date of filing of such documents.

You may request a copy of these filings, at no cost, by writing, emailing or telephoning Citigroup at the following address:

Citigroup Fixed Income Investor Relations

388 Greenwich Street

New York, NY 10013

(212) 559-5091 (tel.)

Email: fixedincomeir@citi.com

You should rely only on the information provided in this prospectus, any applicable pricing supplement, any applicable product supplement, any applicable prospectus supplement and the prospectus, as well as the information incorporated by reference. We have not authorized anyone else to provide you with different information, and we take no responsibility for any information that others may give you. Neither Citigroup nor Citigroup Global Markets Holdings Inc. nor any broker-dealer subsidiary of Citigroup is making an offer of the securities referenced on the cover of this prospectus in any jurisdiction where the making an offer of any of the securities referenced on the cover of this prospectus in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus, any applicable pricing supplement, any applicable product supplement, any applicable prospectus supplement and the prospectus or any documents incorporated by reference is accurate as of any date other than the date of the applicable document.

 

2


FORWARD-LOOKING STATEMENTS

Certain statements in this prospectus and in other information incorporated by reference in this prospectus are “forward-looking statements” within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission. Generally, forward-looking statements are not based on historical facts but instead represent Citigroup’s and its management’s beliefs regarding future events. Such statements may be identified by words such as believe, expect, anticipate, intend, estimate, may increase, may fluctuate, target and illustrative, and similar expressions, or future or conditional verbs such as will, should, would and could.

Such statements are based on management’s current expectations and are subject to risks, uncertainties and changes in circumstances. Actual results and capital and other financial conditions may differ materially from those included in these statements due to a variety of factors, including without limitation the precautionary statements included in this prospectus and any accompanying prospectus supplement, and the factors and uncertainties summarized under “Forward-Looking Statements” in Citigroup’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q and the factors listed and described under “Risk Factors” in Citigroup’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q. Precautionary statements included in such filings should be read in conjunction with this prospectus. Any forward-looking statements made by or on behalf of Citigroup speak only as to the date they are made, and Citigroup does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

 

3


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘424B2’ Filing    Date    Other Filings
Filed on:5/11/21424B2,  8-K,  EFFECT,  FWP
5/6/2110-Q,  424B2,  FWP
3/31/2110-Q,  13F-HR,  13F-NT,  424B2,  424B3,  424B8,  FWP,  PX14A6G
3/17/21424B2,  DEF 14A
2/26/2110-K,  3,  4/A,  424B2,  424B3,  FWP
12/31/2010-K,  11-K,  13F-HR,  13F-NT,  3,  4,  424B2,  424B8,  ABS-15G,  FWP
5/11/0910-Q,  8-K,  S-8,  UPLOAD
 List all Filings 


15 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/06/21  Citigroup Inc.                    10-Q        3/31/21  166:61M
 5/04/21  Citigroup Inc.                    8-K:9       5/04/21   16:464K                                   Donnelley … Solutions/FA
 5/04/21  Citigroup Inc.                    8-K:9       5/04/21   16:468K                                   Donnelley … Solutions/FA
 5/04/21  Citigroup Inc.                    8-K:9       5/04/21   16:449K                                   Donnelley … Solutions/FA
 4/29/21  Citigroup Inc.                    8-K:5,9     4/27/21   13:510K                                   Toppan Merrill/FA
 4/15/21  Citigroup Inc.                    8-K:2,9     4/15/21   14:7M                                     Toppan Merrill/FA
 3/19/21  Citigroup Inc.                    8-K:9       3/19/21   17:353K                                   Donnelley … Solutions/FA
 3/19/21  Citigroup Inc.                    8-K:9       3/19/21   13:339K                                   Davis Polk & … LLP 01/FA
 3/17/21  Citigroup Inc.                    DEF 14A     4/27/21    1:4M                                     DG3/FA
 2/26/21  Citigroup Inc.                    10-K       12/31/20  218:84M
 2/18/21  Citigroup Inc.                    8-K:5,9     2/17/21   17:896K                                   Donnelley … Solutions/FA
 2/12/21  Citigroup Inc.                    8-K:8,9     2/11/21   12:354K                                   Toppan Merrill/FA
 1/28/21  Citigroup Inc.                    8-K:9       1/28/21   16:446K                                   Donnelley … Solutions/FA
 1/15/21  Citigroup Inc.                    8-K:2,9     1/15/21   14:8.7M                                   Toppan Merrill/FA
 5/11/09  Citigroup Inc.                    8-K:8,9     5/11/09    2:31K                                    Toppan Merrill/FA
Top
Filing Submission 0001193125-21-157591   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 6:49:45.2am ET